Diagnosing Inflammatory bowel disease using noninvasive applications of volatile organic compounds: a systematic review

References

• Mozdiak E, O’Malley J, Arasaradnam R. Inflammatory bowel disease. BMJ. 2015;24:351:h4416.
   Google Scholar
• Yamamoto T. The clinical value of faecal calprotectin and lactoferrin measurement in postoperative Crohn’s disease. United European Gastroenterol J. 2015;3:5–10.
   PubMed Web of Science ®Google Scholar
• Vieira A, Fang C, Rolim E, et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Res Notes. 2009;2:1–7.
   PubMedGoogle Scholar
• Dhaliwal A, Zeino Z, Tomkins C, et al. Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply. Frontline Gastroenterol. 2015;6:14–19.
   PubMed Web of Science ®Google Scholar
• Schiller L, Pardi D, Sellin J. Chronic diarrhoea: diagnosis and management. Clin Gastroenterol Hepatol. 2017;15:182–193.
   PubMed Web of Science ®Google Scholar
• Waugh N, Cummins E, Royle P, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess. 2013;17:1–211.
   PubMed Web of Science ®Google Scholar
• Tibble J, Sigthorsson G, Foster R, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut. 1999;45:362–366.
   PubMed Web of Science ®Google Scholar
• von Roon A, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007;102:803–813.
   PubMed Web of Science ®Google Scholar
• Arasaradnam R, Brown S, Forbes A, et al. Guidelines for the investigation of chronic diarrhoea in adults: British society of gastroenterology, 3rd edition. Gut. 2018;67:1–20.
   PubMed Web of Science ®Google Scholar
• Arasaradnam R, Walters J. Role of endoscopy in chronic diarrhoea when functional bowel disease is suspected. Gut. 2018;317730.
   Google Scholar
• Main J, McKenzie H, Yeaman G, et al. Antibody to Saccharomyces cerevisiae (bakers’ yeast) in Crohn’s disease. BMJ. 1988;297:1105–1106.
   PubMed Web of Science ®Google Scholar
• Forcione D, Rosen M, Kisiel J, et al. Anti Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn’s disease. Gut. 2004;53:1117–1122.
   PubMed Web of Science ®Google Scholar
• Wei B, Huang T, Dalwadi H, et al. Pseudomonas fluorescens encodes the Crohn’s disease-associated I2 sequence and T-cell superantigen. Infect Immun. 2002;70:6567–6575.
   PubMed Web of Science ®Google Scholar
• Mitsuyama K, Niwa M, Takedatsu H, et al. Antibody markers in the diagnosis of inflammatory bowel disease. World J Gastroenterol. 2016;22:1304–1310.
   PubMed Web of Science ®Google Scholar
• Ibarra M, Klein-Gitelman M, Morgan E, et al. Serum neopterin levels as a diagnostic marker of hemophagocytic lymphohistiocytosis syndrome. Clin Vaccine Immunol. 2011;18:609–614.
   PubMed Web of Science ®Google Scholar
• Nancey S, Perret-Liaudet A, Moussata D, et al. Urinary neopterin is a valuable tool in monitoring Crohn’s disease activity. Inflamm Bowel Dis. 2008;14:1548–1554.
   PubMed Web of Science ®Google Scholar
• Haunerland N, Spener F. Fatty acid-binding proteins-insights from genetic manipulations. Prog Lipid Res. 2004;43:328–349.
   PubMed Web of Science ®Google Scholar
• Sarikaya M, Ergül B, Doğan Z, et al. Intestinal fatty acid binding protein (I-FABP) as a promising test for Crohn’s disease: a preliminary study. Clin Lab. 2015;61:87–91.
   PubMed Web of Science ®Google Scholar
• Eckmann L, Karin M. NOD2 and Crohn’s disease: loss or gain of function. Immunity. 2005;6:661–666.
   Google Scholar
• Ogura Y, Bonen D, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature. 2001;411:603–606.
   PubMed Web of Science ®Google Scholar
• Alvarez-Lobos M, Arostegui J, Sans M, et al. Crohn’s disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg. 2005;242:693–700.
   PubMed Web of Science ®Google Scholar
• Abreu M, Taylor K, Lin Y, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn’s disease. Gastroenterology. 2002;123:679–688.
   PubMed Web of Science ®Google Scholar
• Sventoraityte J, Zvirbliene A, Franke A, et al. NOD2, IL23R and ATG16L1 polymorphisms in Lithuanian patients with inflammatory bowel disease. World J Gastroenterol. 2010;16:359–364.
   PubMed Web of Science ®Google Scholar
• Naser S, Arce M, Khaja A, et al. Role of ATG16L, NOD2 and IL23R in Crohn’s disease pathogenesis. World J Gastroenterol. 2012;18:412–424.
   PubMed Web of Science ®Google Scholar
• Nwaneri C. Diabetes mellitus: a complete ancient and modern historical perspective. Webmed Cent Diabetes. 2015;6:WMC004831.
   Google Scholar
• Pauling L, Robinson A, Teranishi R, et al. Quantitative analysis of urine vapour and breath by gas liquid partition chromatography. Proc Natl Acad Sci. 1971;68:2374–2376.
   PubMed Web of Science ®Google Scholar
• McCulloch M, Jezierski T, Broffman M, et al. Diagnostic accuracy of canine scent detection in early-and late-stage lung and breast cancers. Integr Cancer Ther. 2006;5:30–39.
   PubMed Web of Science ®Google Scholar
• Sonoda H, Kohnoe S, Yamazato T, et al. Colorectal cancer screening with odour material by canine scent detection. Gut. 2011;60:814–819.
   PubMed Web of Science ®Google Scholar
• Persaud K, Dodd G. Analysis of discrimination mechanisms in the mammalian olfactory system using a model nose. Nature. 1992;299:352–355.
   Google Scholar
• Sedgh S, Keshavarzian A, Klamut M, et al. Elevated breath ethane levels inactive ulcerative colitis: evidence for excessive lipid peroxidation. Am J Gastroenterol. 1994;89:2217–2221.
   PubMed Web of Science ®Google Scholar
• Arasaradnam R, Covington J, Harmston C, et al. Review article: next generation diagnostic modalities in gastroenterology - gas phase volatile compound biomarker detection. Aliment Pharmacol Ther. 2014;39:780–789.
   PubMed Web of Science ®Google Scholar
• Defois C, Ratel J, Garrait G, et al. Food chemicals disrupt human gut microbiota activity and impact intestinal homeostasis as revealed by in vitro systems. Sci Rep. 2018;8:11006.
   PubMed Web of Science ®Google Scholar
• McFarlane M, Millard A, Hall H, et al. Urinary volatile organic compounds and faecal microbiome profiles in colorectal cancer. Colorectal Dis. 2019 Jul 8. DOI:10.1111/codi.14739. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Widlak M, Neal M, Daulton E, et al. Risk stratification of symptomatic patients suspected of colorectal cancer using faecal and urinary markers. Colorectal Dis. 2018;20:335–342.
   PubMed Web of Science ®Google Scholar
• Mozdiak E, Wicaksono A, Covington J, et al. Colorectal cancer and adenoma screening using urinary volatile organic compound (VOC) detection: early results from a single-centre bowel screening population (UK BCSP). Tech Coloproctol. 2019;23:343–351.
   PubMed Web of Science ®Google Scholar
• Kokoszka J, Nelson R, Swedler W, et al. Determination of inflammatory bowel disease activity by breath pentane analysis. Dis Colon Rectum. 1993;36:597–601.
   PubMed Web of Science ®Google Scholar
• Pelli M, Trovarelli G, Capodicasa E, et al. Breath alkanes determination in ulcerative colitis and Crohn’s disease. Dis Colon Rectum. 1999;42:71–76.
   PubMed Web of Science ®Google Scholar
• Bosch S, van Gaal N, Zuurbier R, et al. Differentiation between paediatric irritable bowel syndrome and inflammatory bowel disease based on faecal scent: proof of principle study. Inflamm Bowel Dis. 2018;24:2468–2475.
   PubMed Web of Science ®Google Scholar
• Bosch S, El Manouni El Hassani S, Covington J, et al. Optimized sampling conditions for faecal volatile organic compound analysis by means of field asymmetric ion mobility spectrometry. Anal Chem. 2018;90:7972–7981.
   PubMed Web of Science ®Google Scholar
• van Gaal N, Lakenman R, Covington J, et al. Faecal volatile organic compounds analysis using field asymmetric ion mobility spectrometry: non-invasive diagnostics in paediatric inflammatory bowel disease. J Breath Res. 2017;12:016006.
   PubMed Web of Science ®Google Scholar
• Ahmed I, Greenwood R, Costello B, et al. Investigation of faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease. Aliment Pharmacol Ther. 2016;43:596–611.
   PubMed Web of Science ®Google Scholar
• de Meij T, de Boer N, Benninga M, et al. Faecal gas analysis by electronic nose as novel, non-invasive method for assessment of active and quiescent paediatric inflammatory bowel disease: proof of principle study. J Crohns Colitis. 2014;14:S1873–9946.
   Google Scholar
• Levine J, Ellis C, Furne J, et al. Faecal hydrogen sulfide production in ulcerative colitis. Am J Gastroenterol. 1998;93:83–87.
   PubMed Web of Science ®Google Scholar
• Smolinska A, Bodelier A, Dallinga J, et al. The potential of volatile organic compounds for the detection of active disease in patients with ulcerative colitis. Aliment Pharmacol Ther. 2017;45:1244–1254.
   PubMed Web of Science ®Google Scholar
• Tiele A, Wicaksono A, Kansara J, et al. Breath analysis using eNose and ion mobility technology to diagnose inflammatory bowel disease-a pilot study. Biosensors (Basel). 2019;9(2):55.
   Google Scholar
• Smolinska A, Tedjo D, Blanchet L, et al. Volatile metabolites in breath strongly correlate with gut microbiome in CD patients. Anal Chim Acta. 2018;1025:1–11.
   PubMed Web of Science ®Google Scholar
• Monasta L, Pierobon C, Princivalle A, et al. Inflammatory bowel disease and patterns of volatile organic compounds in the exhaled breath of children: A case-control study using ion molecule reaction-mass spectrometry. PLoS One. 2017;12:e0184118.
   PubMed Web of Science ®Google Scholar
• Dryahina K, Smith D, Bortlík M, et al. Pentane and other volatile organic compounds, including carboxylic acids, in the exhaled breath of patients with Crohn’s disease and ulcerative colitis. J Breath Res. 2017;12(1):016002.
   PubMed Web of Science ®Google Scholar
• Rieder F, Kurada S, Grove D, et al. A distinct colon-derived breath metabolome is associated with inflammatory bowel disease, but not its complications. Clin Transl Gastroenterol. 2016;7(11):e201.
   PubMed Web of Science ®Google Scholar
• Arasaradnam R, McFarlane M, Daulton E, et al. Non-invasive exhaled volatile organic biomarker analysis to detect inflammatory bowel disease (IBD). Dig Liver Dis. 2016;48:148–153.
   PubMedGoogle Scholar
• Bodelier A, Smolinska A, Baranska A, et al. Volatile organic compounds in exhaled air as novel marker for disease activity in Crohn’s disease: a metabolomic approach. Inflamm Bowel Dis. 2015;21:1776–1785.
   PubMed Web of Science ®Google Scholar
• Hicks L, Huang J, Kumar S, et al. Analysis of exhaled breath volatile organic compounds in inflammatory bowel disease: a pilot study. J Crohns Colitis. 2015;9:731–737.
   PubMed Web of Science ®Google Scholar
• Kurada S, Alkhouri N, Fiocchi C, et al. Breath analysis in inflammatory bowel diseases. Aliment Pharmacol Ther. 2015;41:329–341.
   PubMed Web of Science ®Google Scholar
• Markar S, Wiggins T, Kumar S, et al. Exhaled breath analysis for the diagnosis and assessment of endoluminal gastrointestinal diseases. J Clin Gastroenterol. 2015;49:1–8.
   PubMed Web of Science ®Google Scholar
• Patel N, Alkhouri N, Eng K, et al. Metabolomic analysis of breath volatile organic compounds reveals unique breath prints in children with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther. 2014;40:498–507.
   PubMed Web of Science ®Google Scholar
• Arasaradnam R, Ouaret N, Thomas M, et al. A novel tool for noninvasive diagnosis and tracking of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:999–1003.
   PubMed Web of Science ®Google Scholar
• Arasaradnam R, Quraishi N, Kyrou I, et al. Insights into ‘fermentonomics’: evaluation of volatile organic compounds (VOCs) in human disease using an electronic ‘e-nose’. J Med Eng Technol. 2011;35:87–91.
   PubMedGoogle Scholar
• Esfahani S, Wicaksono A, Mozdiak E, et al. Non-invasive diagnosis of diabetes by volatile organic compounds in urine using FAIMS and Fox4000 electronic nose. Biosensors (Basel). 2018;1(8(4)):121.
   Google Scholar